A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Conditions

• Primary IgA Nephropathy

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Sefaxersen (RO7434656) — DRUG
  Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified.
• Placebo — DRUG
  Matching placebo will be administered as SC injection per schedule as specified.

Study Details

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

Key Dates

Start date

Aug 8, 2023

Status verified

May 2026

Primary completion

Aug 31, 2026

Completion

Mar 31, 2029

Study Design

Enrollment

428 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Sefaxersen (RO7434656)
  Participants will receive subcutaneous (SC) doses of sefaxersen (RO7434656) on Days 1, 15, and 29 followed by once every 4 weeks (Q4W) until Week 105. Participants may be eligible to switch to open-label treatment after Week 105 at the investigator's discretion until up to 1 year after the common-close timepoint, the date when the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.
• Placebo Comparator: Placebo
  Participants will receive SC doses of sefaxersen (RO7434656) matching placebo on Days 1, 15, and 29 followed by once Q4W until Week 105. Participants may be eligible to switch to open-label treatment after Week 105 at the investigator's discretion until up to 1 year after the common-close timepoint, the date when the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.

Primary Outcome Measure

Change From Baseline in the Urine Protein-to-Creatinine Ratio (UPCR) at Week 37 [ Time Frame: Baseline, Week 37 ]

Central Contacts

• WA43966 https://forpatients.roche.com/
  888-662-6728 (U.S. Only)
  [email protected]

Locations (40)

Find similar trials in Alabaster, AL